View Older Stories View More Recent Stories

Sep 5, 2023 08:00AM Daré Bioscience Completes Previously Announced Equity Financing
Aug 30, 2023 08:00AM Dare Bioscience (DARE) Announces 10M Share Offering at $0.70/sh
Aug 30, 2023 08:00AM Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aug 10, 2023 08:00AM Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
Aug 9, 2023 08:01AM Dare Bioscience (DARE) Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Tri
Aug 9, 2023 08:00AM Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of
Aug 3, 2023 08:00AM Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
Jul 31, 2023 08:00AM Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
Jul 11, 2023 05:30PM Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
Jul 11, 2023 08:00AM Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
Jul 6, 2023 08:00AM Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Jul 5, 2023 08:00AM Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vagino
Jun 21, 2023 08:00AM Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Pos
Jun 14, 2023 08:00AM Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
Jun 9, 2023 08:00AM Dare Bioscience (DARE) Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1
Jun 9, 2023 08:00AM Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, t
Jun 5, 2023 08:03AM Dare Bioscience (DARE) Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study
Jun 5, 2023 08:00AM Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Jun 1, 2023 08:00AM Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
May 31, 2023 08:00AM Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine
May 11, 2023 08:00AM Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
May 4, 2023 08:00AM Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
Apr 20, 2023 08:00AM Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
Apr 19, 2023 08:00AM David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
Apr 18, 2023 08:01AM Dare Bioscience (DARE) Announces Publication of Positive Safety and Acceptability Data from Phase 1 Trial of DARE-HRT1
Apr 18, 2023 08:00AM Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Thera
Apr 17, 2023 08:00AM Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
Mar 30, 2023 08:00AM Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Mar 23, 2023 08:00AM Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
Mar 1, 2023 08:00AM Daré Bioscience to Present at the 35th Annual Roth Conference
Feb 22, 2023 08:00AM Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
Feb 1, 2023 08:00AM Daré Bioscience to Participate in Three February Conferences
Jan 26, 2023 08:01AM Dare Bioscience (DARE) Announces Publication of Data from Phase 1 Trial of DARE-HRT1
Jan 26, 2023 08:00AM Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective
Jan 9, 2023 08:01AM Dare Bioscience (DARE) Reports Positive PK Results from the DARE-HRT1 Phase 1/2 Study
Jan 9, 2023 08:00AM Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vag
Dec 12, 2022 08:09AM Dare Bioscience (DARE) Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
Dec 12, 2022 08:00AM Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
Nov 15, 2022 08:00AM Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
Nov 14, 2022 08:00AM Dare Bioscience (DARE) Announces Positive Topline Results from DARE-VVA1 Study
Nov 14, 2022 08:00AM Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
Nov 10, 2022 05:45AM Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
Nov 8, 2022 08:00AM Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
Nov 3, 2022 08:00AM Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
Nov 1, 2022 08:00AM Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
Oct 17, 2022 08:04AM Dare Bioscience (DARE) Reports Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
Oct 17, 2022 08:00AM Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
Oct 10, 2022 08:03AM Dare Bioscience (DARE) Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovapren
Oct 10, 2022 08:00AM Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Sep 15, 2022 08:00AM Daré Bioscience to Participate in Two Upcoming Conferences
View More Recent Stories View Older Stories